COMMUNIQUÉS West-GlobeNewswire

NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy
04/02/2026
Rapid progress from announcement of successful launch in under two weeks signals NewGen’s expertise and commitment Launch represents fulfilment of NewGen’s goals to spearhead Real World Asset tokenization, puts Company [...]
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
04/02/2026
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE [...]
R1 Awarded ‘Best in KLAS’ Across Multiple RCM Categories for 2026
04/02/2026
Providers Recognize R1 for Unwavering Commitment to Launching Innovative Technology CHICAGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a [...]
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
04/02/2026
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” [...]
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
04/02/2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Revolo to Present at the 2026 AAAAI Annual Meeting
04/02/2026
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present a poster on its lead candidate, IRL201104 (‘1104), at the [...]
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
04/02/2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – [...]
Control the Stack, Control the Future: The New Era of Supply-Chain Power
04/02/2026
DENVER, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Innovation still rules, but ownership of the entire supply-chain pipeline is becoming the next biggest strategic advantage in today’s markets. From raw inputs to final delivery [...]
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
04/02/2026
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong [...]
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
04/02/2026
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with [...]
Imprivata Enterprise Access Management Wins 2026 Best in KLAS Award for Access Management
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading provider of access management solutions for healthcare and other mission-critical industries, today announced that Imprivata Enterprise Access [...]
SAB BIO to Participate in Upcoming Investor Conferences
04/02/2026
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Levicept Announces the Appointment of James Sandy as Chief Development Officer
04/02/2026
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of [...]
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
04/02/2026
Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical [...]
Experience Truly Natural Results: Aesthetics International Leads the Region with Expressive Botox Expertise
04/02/2026
The Era of "Invisible" Enhancements: Aesthetics International Introduces Expressive Botox to Dubai’s Elite Wellness Scene DUBAI, United Arab Emirates, Feb. 04, 2026 (GLOBE NEWSWIRE) -- As Dubai solidifies its reputation [...]
Novo Nordisk initiates 2026 share repurchase programme
04/02/2026
Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo Nordisk A/S today [...]
Michigan Integrative Health Expands Stem Cell Therapy Services to Welcome Canadian Patients
04/02/2026
DETROIT, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Michigan Integrative Health Stem Cells , a leading provider of stem cell therapy and regenerative medicine in Shelby Township, Michigan, announces the expansion of its service [...]
Novo Nordisk has published its annual report for 2025
04/02/2026
Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format. [...]
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
04/02/2026
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today [...]

Pages